S. Martin

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

G. Remington, P. Llorca, W. Fleischhacker, 2003, The Journal of clinical psychiatry.

Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials

M. Srisurapanont, N. Maneeton, B. Maneeton, 2011, Psychiatry and clinical neurosciences.

Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD

M. Srisurapanont, N. Maneeton, B. Maneeton, 2014, Drug design, development and therapy.

Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials

M. Srisurapanont, N. Maneeton, B. Maneeton, 2012, BMC Psychiatry.

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

H. Möller, P. Llorca, E. Sacchetti, 2005, International clinical psychopharmacology.

The InterSePT scale for suicidal thinking reliability and validity

Larry Alphs, R. Emsley, P. Czobor, 2003, Schizophrenia Research.

Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone

D. Pratt, Z. Huq, S. Libretto, 2003, Current medical research and opinion.

Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials

M. Srisurapanont, N. Maneeton, B. Maneeton, 2011, Psychiatry and clinical neurosciences.